Profound Medical Corp

Profound Medical Corp gears up for Q1 2026 results, spotlighting AI‑powered, incision‑free prostate therapy that promises precision and fewer side‑effects, while engaging investors to gauge future revenue growth and market acceptance.

Profound Medical Corp. upsizes its private placement to $6.45 M, bolstering sales, R&D, and pipeline growth for localized prostate cancer treatments.

Profound Medical Corp: Revolutionizing localized prostate cancer treatment with cutting‑edge tech, strong market recovery, and a global focus on innovation.